Psyence Biomedical Ltd. (NASDAQ: PBM) announced it holds pharmaceutical-grade ibogaine doses in inventory and has established a supply chain through its collaboration with PsyLabs, according to a company statement.

The clinical-stage biopharmaceutical company said it operates what it describes as a vertically integrated platform spanning sourcing, extraction, purification, and pharmaceutical production. The platform operates in Africa at the natural source of ibogaine and includes GMP-compliant manufacturing capabilities.

The company confirmed it currently maintains standardized, stabilized, and GMP-compliant ibogaine doses designed to support research initiatives. The supply aims to provide access to pharmaceutical-grade material for clinical research programs.

"Recent regulatory signals underscore what we have believed for some time – that ibogaine warrants rigorous, structured evaluation," said Jody Aufrichtig, Chief Executive Officer of Psyence BioMed. "Over the past year, we have been building toward this moment – establishing supply, manufacturing capability, and inventory so that we are ready to support clinical research as regulatory pathways evolve."

Through PsyLabs, the company has secured direct access to raw materials and processing capabilities in Africa. PsyLabs operates from an ISO 22000 and GMP-compliant facility and is federally licensed to cultivate, extract, and export psychedelic compounds including ibogaine.

The company produces both high-purity ibogaine and total alkaloid extracts to support different therapeutic approaches. PsyLabs has previously exported psilocybin products to Canada, the UK, Portugal, and Slovenia.

Psyence BioMed positions itself to support partners across early-stage research through clinical development in a market where the company states access to pharmaceutical-grade ibogaine remains limited globally.